REINACH, Switzerland, December 19 Arpida Ltd.(SWX: ARPN) announces positive top-line data of the Phase II'intravenous-to-oral' switch trial with oral iclaprim in patients withcomplicated Skin and Skin Structure Infections (cSSSI).
The top-line results demonstrated high clinical cure rates of over 90%following the step-down therapy with oral iclaprim administered after twodays of initial treatment with intravenous vancomycin. In the Per Protocolpopulation 27/29 patients in the oral iclaprim arm were cured, as compared to28/28 following continuous treatment with intravenous vancomycin. Eradicationrates for S. aureus, the major causative pathogen, were high with 85% in theoral iclaprim arm, and similar to intravenous vancomycin (89%). Iclaprim waswell tolerated; adverse events were infrequent and not significantlydifferent between both study arms. Importantly, no drug-related seriousadverse events occurred and there were no patient withdrawals due to adverseevents.
This press release contains specific forward-looking statements, e.g.statements including terms like believe, assume, expect or similarexpressions. Such forward-looking statements are subject to known and unknownrisks, uncertainties and other factors which may result in a substantialdivergence between the actual results, financial situation, development orperformance of the company and those explicitly or implicitly presumed inthese statements. Against the background of these uncertainties readersshould not place undue reliance on forward-looking statements. The companyassumes no responsibility to update forward-looking statements or to adaptthem to future events or developments.
This statement was also released in German and French. The Englishoriginal is the binding version.Arpida contacts: Dr Jurgen Raths, President and CEO, Tel: +41-61-417-96-60. Harry Welten, MBA, CFO and Senior Vice President, Tel: +41-61-417-96-65. Paul Verbraeken, Head of Corporate Communications, Tel: +41-61-417-96-83.
SOURCE Arpida Ltd.